A biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, temozolamide, interferon alfa, and interleukin-2 for metastatic melanoma.

被引：0
|
作者：
Ron, IG [1 ]
Ryvo, L [1 ]
Sarid, D [1 ]
Asna, N [1 ]
Inbar, MJ [1 ]
机构：
[1] Tel Aviv Med Ctr & Sch Med, IL-64239 Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7567
引用
收藏
页码：726S / 726S
页数：1
相关论文
共 50 条
  • [41] ROLE OF RECOMBINANT INTERLEUKIN-2 IN COMBINATION WITH INTERFERON-ALFA AND CHEMOTHERAPY IN THE TREATMENT OF ADVANCED MELANOMA
    LEGHA, SS
    BUZAID, AC
    SEMINARS IN ONCOLOGY, 1993, 20 (06) : 27 - 32
  • [42] Subcutaneous low doses of interleukin-2 and recombinant interferon alpha with carboplatin and vinblastine in patients with advanced melanoma
    Bafaloukos, D
    Fountzilas, G
    Skarlos, D
    Pavlidis, N
    Bakoyiannis, C
    Karvounis, N
    Kosmidis, P
    ONCOLOGY, 1998, 55 (01) : 48 - 52
  • [43] SUCCESSFUL THERAPY OF METASTATIC ECCRINE POROMA USING PERILESIONAL INTERFERON-ALFA AND INTERLEUKIN-2
    DUMMER, R
    BECKER, JC
    BOSER, B
    HARTMANN, AA
    BURG, G
    ARCHIVES OF DERMATOLOGY, 1992, 128 (08) : 1127 - 1128
  • [44] CUTANEOUS SIDE-EFFECTS ASSOCIATED WITH INTERLEUKIN-2 ADMINISTRATION FOR METASTATIC MELANOMA
    WOLKENSTEIN, P
    CHOSIDOW, O
    WECHSLER, J
    GUILLAUME, JC
    LESCS, MC
    BRANDELY, M
    AVRIL, MF
    REVUZ, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 28 (01) : 66 - 70
  • [45] CHEMOIMMUNOTHERAPY OF METASTATIC MELANOMA - CISPLATIN, INTERLEUKIN-2 AND IFN-ALPHA IN 91 PATIENTS
    RIXE, O
    BENHAMMOUDA, A
    ANTOINE, E
    PETIT, T
    TOURANI, JM
    BOREL, C
    FRANKS, C
    KALIF, B
    MOUSSEAU, M
    THOMAS, A
    BENSFIA, S
    NIZRI, D
    SOUBRANE, C
    HERRERA, A
    BIZZARI, JP
    AUCLERC, G
    WEIL, M
    BANZET, P
    KHAYAT, D
    PATHOLOGIE BIOLOGIE, 1994, 42 (10): : 1080 - 1081
  • [46] Interferon α (IFNα), interleukin-2 (IL-2) and cisplatin (CDDP) in metastatic melanoma (MM) and advanced soft tissue sarcoma (ASTS).
    Botto, HG
    Otegui, ML
    Botto, ME
    Delia, R
    Rios, M
    ANNALS OF ONCOLOGY, 2000, 11 : 127 - 128
  • [47] Results of the first line biochemotherapy with interleukin-2 (IL2), interferon (IFN) and 5-FU and second line biochemotherapy with retinoids and interferon in metastatic renal cell carcinoma (MRCC)
    Zemanova, M
    Petruzelka, L
    ANNALS OF ONCOLOGY, 1998, 9 : 62 - 62
  • [48] Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma
    Lindnér, P
    Rizell, M
    Mattsson, J
    Hellstrand, K
    Naredi, P
    ANTICANCER RESEARCH, 2004, 24 (3B) : 1837 - 1842
  • [49] A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma
    Ready, N
    Aronson, F
    Wanebo, H
    Kennedy, T
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (05): : 479 - 484
  • [50] Effect of Interferon-α-2b and Interleukin-2 Combined with Chemotherapy in Metastatic Melanoma
    Su, Zheng
    Shi, Fen
    Zhang, Jian
    Liang, Weiqiang
    PANMINERVA MEDICA, 2020, : 131 - 136
12345